Nephrology

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

New research is shining light on the use of eGFR as a biomarker for increased cardiovascular risk.

The intravenous approach can be used regardless of what bicarbonate delivery method a dialysis center uses.

A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.

Azathioprine is linked to a slightly higher eGFR for patients with inflammatory bowel disease.

Coronary microvascular dysfunction is independently related to abnormal cardiac mechanics, according to a new study.

Higher ACR levels following an acute kidney injury is linked to an increased risk of kidney disease progression.

In a new study, investigators determine the death-censored risk of graft failure with structural kidney feature.

Deceased donor kidneys could offer a solution to a major kidney shortage in the US.

In a new study, investigators suggest coffee may be used in prevention strategies for chronic kidney disease.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

Michael Spigler, vice president of Patient Services and Kidney Disease Education for the American Kidney Fund, talks about the challenges and future of nephrology during Kidney Week.

Investigators examine how different supplementation impacts kidney function in patients with type 2 diabetes.

Investigators present data from the CREDENCE trial during AHA.

Taking a routine invasive approach had no impact on clinical outcomes or quality of life in patients with chronic kidney disease as well as stable ischemic heart disease.

With ARBs linked to a higher risk of suicide, investigators suggest treating diseases like hypertension, chronic kidney disease, heart failure, and diabetes with ACEIs instead.

The results of a new survey regarding quality of care for end stage renal disease patients raise questions about how to improve the quality of end-of-life care.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

In an extensive review of 18 cohort studies, investigators connect dietary patterns with chronic kidney disease incidence rates.

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

The CREDENCE study of canagliflozin in adults with chronic kidney disease and type 2 diabetes met its primary endpoint as well as cardiovascular endpoints.

The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Positive data collected from 2 phase 2 trials evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) have been reported.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Dimerix shares update on DMX-200, a combination therapy of propagermanium and irbesartan for the treatment of focal segmental sclerosis in addition to chronic kidney disease.